Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com. Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.
FDA approved Abbvies risakizumab-rzaa
A new way of inhibiting tumor necrosis factor (TNF) for treating rheumatoid arthritis showed strong results in a phase II/III clinical trial, researchers said.
About 75% to 80% of patients receiving an investigational agent called ozoralizumab achieved 20% reductions in symptoms by
Read Article
Links:
Links:
Links:
Links:
A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal.
Read Article
Links:
Links:
There is a shortage of rheumatologists in Canada and the recent 2020 Canadian Rheumatology Association (CRA) Workforce and Wellness study shows that the shortage may be compounded by rheumatologist burnout, especially among young and female physicians.
Read Article
Annals of Internal Medicine reports that thiopurine toxcicity risk is associated with the "CC" genotype and that azathioprine discontinuation was associated with hematopoietic toxicity and lower thiopurine doses.
Prior studies have shown that azathiprine (AZA) use is associated with
Read Article
Links:
Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.
Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast
Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.
For one, patients using inhibitors of the Janus-associated kinase (JAK) pathway were more likely to stop them because of adverse
Read Article
Links:
Links:
Dr. John Cush @RheumNow( View Tweet )
Pyoderma gangrenosum (PG) is rare, but often associated with different forms of arthritis, in particular rheumatoid arthritis and inflammatory bowel diseases.
Read ArticleDr. John Cush @RheumNow( View Tweet )
Links:
Links:
Links:
Links:
Links:
Dr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media
Read Article
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
To recap, it was an FDA-mandated, open-label, randomized controlled trial that had high CV risk patients with active RA, on background stable dose
Read Article
Discussions on drug safety can be as treacherous as quicksand for the patient and physician. What the physician knows and what the patient perceives may not be in sync.
Read Post
